[Therapy of perioperative sinus tachycardia with the new calcium antagonist falipamil].
The haemodynamic responses after application of 100-200 mg falipamil (5,6-dimethoxy-2-(3-((alpha (3,4-dimethoxy)-phenylethyl) methylamino)propyl)phthalimidine, AQ-A 39) a new calcium channel blocker with specific action on the sinus node, was studied in 11 patients with perioperative sinus tachycardia (greater than 120/min). A drop in the heart rate of at least 10% could be observed in all patients. In 8 patients 100 mg falipamil decreased the mean heart rate from 130 +/- 19 to 97 +/- 8/min 5 min after the application (p less than 0.001). In the resting 3 patients a second dose of falipamil was injected because of insufficient clinical response. In these patients the mean heart rate dropped from 162 +/- 27 to 125 +/- 40/min 10 min after the second dose. No significant changes of the blood pressure could be observed. Falipamil may become a valuable drug for the therapy of sinus tachycardia due to catecholamines during the perioperative period.
Tryba
M
M
Universitätsklinik für Anaesthesiologie, Intensiv- und Schmerztherapie, Bergmannsheil, Bochum.
Zenz
M
M
D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy*; D054833:Isoindoles; D008297:Male; D008875:Middle Aged; D010797:Phthalimides / Q000627:therapeutic use*; D013616:Tachycardia, Sinus / Q000188:drug therapy*; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*
D002121:Calcium Channel Blockers; D054833:Isoindoles; D010797:Phthalimides; C030532:falipamil
Therapie perioperativer Sinustachykardien mit dem neuen Kalzium-Antagonisten Falipamil.